Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Curocell, Inc.

https://curocellbtx.com/

Latest From Curocell, Inc.

Japan Looks For Role As Korean Ventures’ New Step To Global Market

Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.

Japan South Korea

Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

South Korea Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register